Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
X4 Pharmaceuticals Inc Is A Biopharmaceutical Company Developing And Commercializing Novel Therapeutics For The Treatment Of Rare Hematology Diseases. The Company'S Clinical Candidate Is Mavorixafor, A Small Molecule Antagonist Of The Chemokine Receptor Cxcr4 That Is Being Developed As An Oral, Once-Daily Therapy. It Can Increase The Mobilization Of Mature, Functional White Blood Cells From The Bone Marrow Into The Bloodstream. It Also Has Two Pre-Clinical Candidates X4p-003 And X4p-002 Which Are Cxcr4 Antagonists With Different Properties.